Trial Profile
A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Custirsen (Primary) ; Dexamethasone; Moxifloxacin
- Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacodynamics
- Sponsors OncoGenex Technologies
- 22 Jan 2014 According to the ClinicalTrials.gov record, Status changed from recruiting to completed.
- 18 Jun 2013 New trial record